J.Carl Barrett
Founder
Precede Biosciences
Precede Biosciences provides a liquid‑biopsy platform that extracts circulating chromatin and DNA methylation from 1 mL of plasma to deliver genome‑wide, quantitative profiles of transcriptional activity, pathway activation, and cell‑state changes. Their proprietary machine‑learning pipelines translate these epigenomic signals into interpretable reports for longitudinal disease monitoring, supporting drug development, patient selection, and response tracking for pharmaceutical and biotech companies.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Raised to date
$57MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current precision medicine approaches rely on invasive tissue biopsies or static biomarkers, limiting the ability to monitor disease biology in real time and to guide drug development and patient selection dynamically.
Solution
Precede Biosciences offers a liquid‑biopsy platform that extracts and decodes circulating chromatin and DNA methylation patterns from just 1 mL of plasma. By profiling ~20 K gene promoters, ~1 M enhancers and ~50 K CpG islands, the platform provides genome‑wide, quantitative readouts of transcriptional activity, pathway activation, and cell‑state changes. Proprietary machine‑learning models translate these signals into interpretable reports that reflect disease behavior over time, enabling longitudinal tracking without repeated tissue sampling. The technology is delivered through two products: Precede Bio Insight™ for comprehensive, consistent profiling across patients and timepoints, and Precede Bio Dx™ for non‑invasive patient selection and biomarker‑driven decisions in clinical trials.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing targeted therapies, as well as clinical‑trial organizations that require non‑invasive biomarker data for patient selection and response monitoring.
Features
- Liquid‑biopsy assay requiring only 1 mL of plasma to capture circulating chromatin and DNA methylome
- Genome‑wide coverage of ~20 K promoters, ~1 M enhancers, and ~50 K CpG islands for high‑resolution transcriptional profiling
- Quantitative measurements that correlate strongly with tissue‑based biomarkers, supporting consistent longitudinal monitoring
- Proprietary machine‑learning pipelines that convert epigenomic data into actionable pathway and target activity scores
- Two product tiers: Bio Insight™ for broad research and development use, and Bio Dx™ for clinical‑trial patient selection and stratification
- Scalable workflow compatible with standard blood‑draw procedures, enabling deployment across multiple sites